Close Menu

Personal Genome Diagnostics

Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.

The firms will provide access to tumor profiling tests for both tissue and plasma samples, specifically PGDx's elio tissue complete and elio plasma resolve assays.

The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.

The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.

The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.

The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples.

The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.

A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.